Paradigm Biocapital Advisors LP
Annual return '25
+22.7%
SPY '25
+17.7%
Alpha
+5.0ptsvs SPY
Invested
$4.9B
Holdings
35
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 97%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$ACLX
ARCELLX INC
Held since at least Q1 2024
13.5%
02
$RVMD
REVOLUTION MEDICINES INC
Held since at least Q1 2024
13.2%
03
$NUVL
NUVALENT INC
Held since at least Q1 2024
11.1%
04
$PCVX
VAXCYTE INC
Held since at least Q1 2024
5.7%
05
$EWTX
EDGEWISE THERAPEUTICS INC
Held since at least Q1 2024
4.7%
06
$GMAB
GENMAB A/S
Held since at least Q1 2024
4.4%
07
$INSM
INSMED INC
Held since at least Q1 2024
4.2%
08
$TARS
TARSUS PHARMACEUTICALS INC
Held since at least Q1 2024
3.7%
09
$BLTE
BELITE BIO INC
Held since at least Q1 2024
3.6%
10
$ERAS
ERASCA INC
Held since at least Q1 2024
3.4%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 09:28 UTC.